Todd F. Baumgartner, MD, MPH has served as Chief Regulatory Officer of Applied Therapeutics since March 2025. Prior to joining Applied Therapeutics, Dr. Baumgartner served as Senior Vice President of Global Regulatory Affairs, Pharmacovigilance and Biometrics at Ovid Therapeutics from 2020 through 2024, where he oversaw multiple development functions for several pipeline programs, including Regulatory Affairs, Pharmacovigilance, Biometrics, Program Management and Quality Assurance, and served briefly as acting Chief Medical Officer.

Prior to Ovid, Dr. Baumgartner served as Senior Vice President of Regulatory Affairs at Acorda Therapeutics, where he led the Regulatory Affairs and Clinical Operations organizations, heading up the regulatory development and garnering regulatory marketing approvals in the US and Europe for Inbrija™ for Parkinson’s OFF episodes. Previously, he served as Chief Medical Officer of Purdue Pharma and, earlier in his career, held various leadership positions of increasing responsibility at AstraZeneca Pharmaceuticals and Bristol-Myers Squibb. He has served in leadership roles across 12 New Drug Applications.

Dr. Baumgartner obtained an MPH from the University of California-Berkeley, an MD from the University of Missouri-Columbia, and a BA from Duke University. He trained as a resident in Family Medicine at the University of Missouri and completed a residency in Public Health and General Preventative Medicine with the California Department of Health Services and is Board Certified.